Literature DB >> 25408825

Treatment of amyotrophic lateral sclerosis: lessons learned from many failures.

P Hande Ozdinler1, Richard B Silverman2.   

Abstract

Amyotrophic lateral sclerosis (ALS) is one of the most complex neurodegenerative diseases, involving both cortical and spinal components of motor neuron circuitry and non-neuronal cells that support the motor neurons. There is no effective therapeutic for ALS, and compounds that have extended the lifespan of ALS mouse models have failed in clinical trials. This viewpoint discusses current information regarding the changing views about ALS and what the failures in clinical trials can teach us in the search for an effective treatment. Previous challenges and roadblocks in drug discovery for ALS are noted, and solutions to current limitations are discussed. Learning from the past and moving forward with a new mindset can translate into successful and effective treatment strategies in ALS and other related diseases.

Entities:  

Year:  2014        PMID: 25408825      PMCID: PMC4233364          DOI: 10.1021/ml500404b

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  11 in total

Review 1.  Moving forward in clinical trials for ALS: motor neurons lead the way please.

Authors:  Bariş Genç; P Hande Özdinler
Journal:  Drug Discov Today       Date:  2013-10-27       Impact factor: 7.851

Review 2.  Toward more efficient clinical trials for amyotrophic lateral sclerosis.

Authors:  Merit E Cudkowicz; Jon Katz; Dan H Moore; Gilmore O'Neill; Jonathan D Glass; Hiroshi Mitsumoto; Stanley Appel; Bernard Ravina; Karl Kieburtz; Ira Shoulson; Petra Kaufmann; Jaffar Khan; Ericka Simpson; Jeremy Shefner; Bruce Levin; Valerie Cwik; David Schoenfeld; Swati Aggarwal; Michael P McDermott; Robert G Miller
Journal:  Amyotroph Lateral Scler       Date:  2010-05-03

3.  Preclinical research: Make mouse studies work.

Authors:  Steve Perrin
Journal:  Nature       Date:  2014-03-27       Impact factor: 49.962

Review 4.  The past, present and future of stem cell clinical trials for ALS.

Authors:  Gretchen M Thomsen; Genevieve Gowing; Soshana Svendsen; Clive N Svendsen
Journal:  Exp Neurol       Date:  2014-03-06       Impact factor: 5.330

Review 5.  Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies.

Authors:  Steve Vucic; Jeffrey D Rothstein; Matthew C Kiernan
Journal:  Trends Neurosci       Date:  2014-06-11       Impact factor: 13.837

6.  The non-cell-autonomous component of ALS: new in vitro models and future challenges.

Authors:  Laura Ferraiuolo
Journal:  Biochem Soc Trans       Date:  2014-10       Impact factor: 5.407

7.  eGFP expression under UCHL1 promoter genetically labels corticospinal motor neurons and a subpopulation of degeneration-resistant spinal motor neurons in an ALS mouse model.

Authors:  Marina V Yasvoina; Baris Genç; Javier H Jara; Patrick L Sheets; Katharina A Quinlan; Ana Milosevic; Gordon M G Shepherd; C J Heckman; P Hande Özdinler
Journal:  J Neurosci       Date:  2013-05-01       Impact factor: 6.167

Review 8.  Clinical implications of recent breakthroughs in amyotrophic lateral sclerosis.

Authors:  Philip Van Damme; Wim Robberecht
Journal:  Curr Opin Neurol       Date:  2013-10       Impact factor: 5.710

Review 9.  Amyotrophic lateral sclerosis: Problems and prospects.

Authors:  Jemeen Sreedharan; Robert H Brown
Journal:  Ann Neurol       Date:  2013-09       Impact factor: 10.422

10.  Identification of pharmacological targets in amyotrophic lateral sclerosis through genomic analysis of deregulated genes and pathways.

Authors:  Sabrina Paratore; Salvatore Pezzino; Sebastiano Cavallaro
Journal:  Curr Genomics       Date:  2012-06       Impact factor: 2.236

View more
  4 in total

1.  Tertiary Amine Pyrazolones and Their Salts as Inhibitors of Mutant Superoxide Dismutase 1-Dependent Protein Aggregation for the Treatment of Amyotrophic Lateral Sclerosis.

Authors:  Yinan Zhang; Kevin Tianmeng Zhao; Susan G Fox; Jinho Kim; Donald R Kirsch; Robert J Ferrante; Richard I Morimoto; Richard B Silverman
Journal:  J Med Chem       Date:  2015-07-31       Impact factor: 7.446

2.  Better understanding the neurobiology of primary lateral sclerosis.

Authors:  P Hande Ozdinler; Mukesh Gautam; Oge Gozutok; Csaba Konrad; Giovanni Manfredi; Estela Area Gomez; Hiroshi Mitsumoto; Marcella L Erb; Zheng Tian; Georg Haase
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2020-11       Impact factor: 4.092

3.  Riluzole-Triazole Hybrids as Novel Chemical Probes for Neuroprotection in Amyotrophic Lateral Sclerosis.

Authors:  Joseph B Sweeney; Marcus Rattray; Victoria Pugh; Lucy A Powell
Journal:  ACS Med Chem Lett       Date:  2018-05-30       Impact factor: 4.345

4.  Improving mitochondria and ER stability helps eliminate upper motor neuron degeneration that occurs due to mSOD1 toxicity and TDP-43 pathology.

Authors:  Barış Genç; Mukesh Gautam; Öge Gözütok; Ina Dervishi; Santana Sanchez; Gashaw M Goshu; Nuran Koçak; Edward Xie; Richard B Silverman; P Hande Özdinler
Journal:  Clin Transl Med       Date:  2021-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.